Bakhite E, Hassanien R, Farhan N, Sayed E, Sharaky M
BMC Chem. 2025; 19(1):46.
PMID: 39985107
PMC: 11846289.
DOI: 10.1186/s13065-025-01399-0.
Isik F, Thomson S, Cueto J, Spathos J, Breit S, Tsai V
Front Immunol. 2024; 15:1514518.
PMID: 39737171
PMC: 11682991.
DOI: 10.3389/fimmu.2024.1514518.
Xia C, Alliey-Rodriguez N, Tamminga C, Keshavan M, Pearlson G, Keedy S
Mol Psychiatry. 2024; .
PMID: 39709506
DOI: 10.1038/s41380-024-02876-z.
Xia C, Alliey-Rodriguez N, Tamminga C, Keshavan M, Pearlson G, Keedy S
medRxiv. 2024; .
PMID: 39677452
PMC: 11643284.
DOI: 10.1101/2024.12.05.24318404.
Poltavski D, Cunha A, Tan J, Sucov H, Makita T
Elife. 2024; 13.
PMID: 39641974
PMC: 11623925.
DOI: 10.7554/eLife.96424.
Detection of genetic mutations in 855 cases of papillary thyroid carcinoma by next generation sequencing and its clinicopathological features.
Shi D, Yao M, Wu D, Jiang M, Li J, Zheng Y
Diagn Pathol. 2024; 19(1):146.
PMID: 39548512
PMC: 11566394.
DOI: 10.1186/s13000-024-01573-3.
Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC.
Mc Leer A, Mondet J, Magnat N, Mersch M, Giovannini D, Emprou C
JTO Clin Res Rep. 2024; 5(12):100714.
PMID: 39507413
PMC: 11539407.
DOI: 10.1016/j.jtocrr.2024.100714.
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A
Signal Transduct Target Ther. 2024; 9(1):201.
PMID: 39138146
PMC: 11323831.
DOI: 10.1038/s41392-024-01899-w.
Cheminformatics-based identification of phosphorylated RET tyrosine kinase inhibitors for human cancer.
Talukder M, Aktaruzzaman M, Siddiquee N, Islam S, Wani T, Alkahtani H
Front Chem. 2024; 12:1407331.
PMID: 39086985
PMC: 11289668.
DOI: 10.3389/fchem.2024.1407331.
Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease.
Tripathi R, Goyal L, Singh S
Curr Gene Ther. 2024; 24(4):278-291.
PMID: 38310455
DOI: 10.2174/0115665232283842240102073002.
Evaluating the Pharmacokinetics and Pharmacodynamics of Chemotherapeutics within a Spatial SILAC-Labeled Spheroid Model System.
Beller N, Wang Y, Hummon A
Anal Chem. 2023; 95(30):11263-11272.
PMID: 37462741
PMC: 10676637.
DOI: 10.1021/acs.analchem.3c00905.
Pathogenicity of p.Phe147del in RET in familial Hirschsprung's disease.
Wu W, Tan K, Xu W, Liu J, Lv Z
Am J Transl Res. 2023; 15(4):2690-2702.
PMID: 37193168
PMC: 10182518.
IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome.
Araya P, Kinning K, Coughlan C, Smith K, Granrath R, Enriquez-Estrada B
Cell Rep. 2022; 41(13):111883.
PMID: 36577365
PMC: 9876612.
DOI: 10.1016/j.celrep.2022.111883.
Biological Activity , Absorption, BBB Penetration, and Tolerability of Nanoformulation of BT44:RET Agonist with Disease-Modifying Potential for the Treatment of Neurodegeneration.
Haider M, Mahato A, Kotliarova A, Forster S, Bottcher B, Stahlhut P
Biomacromolecules. 2022; 24(10):4348-4365.
PMID: 36219820
PMC: 10565809.
DOI: 10.1021/acs.biomac.2c00761.
Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.
Konstantinou M, Tournier E
Int J Dermatol. 2022; 61(11):1409-1411.
PMID: 35569068
PMC: 9790644.
DOI: 10.1111/ijd.16269.
Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics.
Parate S, Kumar V, Hong J, Lee K
RSC Adv. 2022; 12(2):1194-1207.
PMID: 35425116
PMC: 8978841.
DOI: 10.1039/d1ra07328a.
RET receptor signaling: Function in development, metabolic disease, and cancer.
Takahashi M
Proc Jpn Acad Ser B Phys Biol Sci. 2022; 98(3):112-125.
PMID: 35283407
PMC: 8948417.
DOI: 10.2183/pjab.98.008.
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.
Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J
J Exp Clin Cancer Res. 2022; 41(1):46.
PMID: 35109899
PMC: 8808994.
DOI: 10.1186/s13046-022-02255-y.
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D, Ryan K, Lakkaniga N, Acharya B, Garcia Garcia N, Smith E
J Med Chem. 2021; 64(16):11747-11773.
PMID: 34402300
PMC: 9697126.
DOI: 10.1021/acs.jmedchem.0c02167.
Glial Cell Line-Derived Neurotrophic Factor Family Ligands, Players at the Interface of Neuroinflammation and Neuroprotection: Focus Onto the Glia.
Kotliarova A, Sidorova Y
Front Cell Neurosci. 2021; 15:679034.
PMID: 34220453
PMC: 8250866.
DOI: 10.3389/fncel.2021.679034.